OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq. More information...
According to PR-model, oncomed.com is ranked 3,119,401st in multilingual Wikipedia, in particular this website is ranked 1,684,639th in English Wikipedia.
The website is placed before labf15.org and after examedia.info in the BestRef global ranking of the most important sources of Wikipedia.
